Business

Having been on the fence about an upside case for the S&P for the greater part of 2016, Goldman's chief equity strategist David Kostin finally threw in the towel earlier this week when, as we reported, Goldman raised its S&P price target from 2,100 (as of year end 2016) to 2,400 for mid-year 2017 on what it calls "Trump Hope" (as apparently does everyone else, see "The World Has Changed" - Average S&P Target Before Trump: 2,087; After Trump: 2,425"), which it then sees dipping to 2,300 by year-end 2017 on "Trump Fear."

Submitted by Michael Snyder via The Economic Collapse blog,

With Carrier setting the precedent for what future negotiations with the Trump administration may look like, Ford CEO Mark Fields has come forward to layout potential policy changes that would be important to preserving auto jobs in the United States.  Not surprisingly, per an interview with Bloomberg, Fields' opening "ask" focused on less restrictive fuel economy standards, new currency-manipulation rules to promote free and fair trade and corporate tax reform.

A new study has revealed that almost all US patient advocacy groups are funded and led by the drug industry Patient advocacy groups are supposed to be unbiased and  independent authorities championing the public interest with regard to drug and medical issues before the FDA. They claim to represent the true voice of constituents, untainted by special interest bias.

Submitted by Alasdair Macleod via GoldMoney.com,

The Trump shock produced some unexpected market reactions, partly explained by investors buying into a risk-on argument,equities over bonds and buying dollars by selling other currencies and gold.